Tevogen Bio Holdings Inc.
TVGN
We are a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes ( CTLs ), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sus…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$23M
▼ -91.4% YoY
Op. Margin
–
ROIC
-583.37%
▼ -363.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -3.3% YoY
Op. Cash Flow (TTM)
-$10M
▼ -2.7% YoY
Net Debt
$3M
Cash & Equiv.
$145K
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TVGN
Tevogen Bio Holdings (TVGN) in two numbers
Questions about Tevogen Bio Holdings
Does Tevogen Bio Holdings (TVGN) pay a dividend?
No. Tevogen Bio Holdings (TVGN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 16 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in TVGN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TVGN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.